Literature DB >> 17216258

Effect of haemodialysis on markers of bone turnover in children.

Simon Waller1, Deborah Ridout, Lesley Rees.   

Abstract

'Intact' parathyroid hormone (iPTH) assays are used to measure serum PTH levels in haemodialysis patients to diagnose and monitor secondary hyperparathyroidism and consequent renal osteodystrophy (ROD); these assays exhibit cross-reactivity with long carboxyl-terminal PTH fragments (C-PTH) that accumulate in end stage renal failure (ESRF) and antagonise the biological activity of the whole molecule, 1-84 PTH. The effects of haemodialysis on C-PTH are not known. We investigated how haemodialysis affects serum concentrations of calcium, iPTH, 1-84 PTH, C-PTH, and other markers of bone turnover; bone-specific alkaline phosphatase (BALP) and type 1 collagen cross-linked telopeptide (CTx). Fifteen patients, mean (range) age 13.9 (4.3-17.6) years, haemodialysed for a median of 16.3 (4-41) months, had pre- and post-dialysis serum samples collected for routine biochemistry, BALP, CTx, iPTH and 1-84 PTH assays. Changes to serum concentrations and relationships between these biochemical surrogate markers of ROD were investigated. Serum phosphate and PTH levels (measured by both assays) fell significantly during dialysis, whereas serum calcium, C-PTH, the 1-84 PTH: C-PTH ratio and BALP and CTx concentrations were not significantly changed. 1-84 PTH levels were related to pre but not post dialysis serum calcium levels and changes to 1-84 PTH levels during dialysis were related to changes in serum calcium levels. 1-84 PTH and iPTH were reduced by haemodialysis, whereas levels of BALP and CTx remained stable post-dialysis. The relationship between BALP and CTx and bone histology requires investigation to determine whether they are more useful markers of bone turnover in this patient group.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17216258     DOI: 10.1007/s00467-006-0378-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  31 in total

1.  Serum CrossLaps: pediatric reference intervals from birth to 19 years of age.

Authors:  Patricia M Crofton; Nancy Evans; Mervyn R H Taylor; Celia V Holland
Journal:  Clin Chem       Date:  2002       Impact factor: 8.327

2.  Receptors for the carboxyl-terminal region of pth(1-84) are highly expressed in osteocytic cells.

Authors:  P Divieti; N Inomata; K Chapin; R Singh; H Jüppner; F R Bringhurst
Journal:  Endocrinology       Date:  2001-02       Impact factor: 4.736

3.  High serum levels of a non-(1-84) parathyroid hormone (PTH) fragment in pediatric haemodialysis patients.

Authors:  R Salomon; M Charbit; M F Gagnadoux; P Niaudet; P Gao; T Cantor; J C Souberbielle
Journal:  Pediatr Nephrol       Date:  2001-12       Impact factor: 3.714

4.  RNA-Protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate.

Authors:  E Moallem; R Kilav; J Silver; T Naveh-Many
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

5.  A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure.

Authors:  M R John; W G Goodman; P Gao; T L Cantor; I B Salusky; H Jüppner
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

6.  PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease.

Authors:  Giorgio Coen; Ermanno Bonucci; Paola Ballanti; Alessandro Balducci; Santo Calabria; Giulia A Nicolai; Maria Stephanie Fischer; Francesca Lifrieri; Micaela Manni; Massimo Morosetti; Eleonora Moscaritolo; Daniela Sardella
Journal:  Am J Kidney Dis       Date:  2002-08       Impact factor: 8.860

7.  Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients.

Authors:  M E Solal; J L Sebert; B Boudailliez; A Marie; P Moriniere; J Gueris; R Bouillon; A Fournier
Journal:  J Clin Endocrinol Metab       Date:  1991-09       Impact factor: 5.958

8.  Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum.

Authors:  B Gomez; S Ardakani; J Ju; D Jenkins; M J Cerelli; G Y Daniloff; V T Kung
Journal:  Clin Chem       Date:  1995-11       Impact factor: 8.327

9.  Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease.

Authors:  A J Hutchison; R W Whitehouse; H F Boulton; J E Adams; E B Mawer; T J Freemont; R Gokal
Journal:  Kidney Int       Date:  1993-11       Impact factor: 10.612

10.  Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure.

Authors:  M Chris Langub; Marie-Claude Monier-Faugere; Guodong Wang; John P Williams; Nicholas J Koszewski; Hartmut H Malluche
Journal:  Endocrinology       Date:  2003-04       Impact factor: 4.736

View more
  2 in total

1.  Effects of bone and mineral metabolism on arterial elasticity in chronic renal failure.

Authors:  Eva Kis; Orsolya Cseprekál; Edina Bíró; Kata Kelen; Dóra Ferenczi; Andrea Kerti; Attila J Szabó; Antal Szabó; György S Reusz
Journal:  Pediatr Nephrol       Date:  2009-12       Impact factor: 3.714

2.  Osteogenic scaffolds for bone reconstruction.

Authors:  Ling-Jiang Li; Ning Liu; Jian-Gang Shi; Qing Liu; Lian-Shun Jia; Wen Yuan
Journal:  Biores Open Access       Date:  2012-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.